Eliciting Preferences for Drug Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Watson, Verity; Ryan, Mandy; Brown, Christian; Barnett, G. S.; Ellis, B.; Emberton, Mark

doi:10.1097/01.ju.0000140957.31325.7f

Cited by 63 publications

(65 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They include watchful waiting, medical therapy with α-blockers or 5 α-reductase inhibitors, hormone therapy, surgery and phytotherapy (Watson et al, 2004;Kaplan, 2006). The use of complementary and alternative medicine (CAM) for the treatment of BPH is becoming popular.…”

Section: Introductionmentioning

confidence: 99%

Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing <i>Telfairia occidentalis</i> seeds

Ejike

Ezeanyika²

2011

Afr. J. Trad. Compl. Alt. Med.

View full text Add to dashboard Cite

The usefulness of diet containing Telfairia occidentalis seeds, in managing benign prostatic hyperplasia (BPH) in rats was studied. Twenty male Wistar rats were divided into four equal groups. BPH was induced by sub-cutaneous injection of dihydrotestosterone (DHT) and estradiol valerate (ratio, 10:1) every other day for 28 days. Rats in the test group were placed on the test diet for 7 days following disease induction. One control group (DC) was fed on a normal diet for 7 days following disease induction. Two other control groups, HC and HDC, were given sub-cutaneous olive oil (vehicle) for the same duration, and placed on the test diet and normal diet, respectively. Markers of BPH, and hormone profile were determined using standard methods. The results show that relative prostate weight and protein content of the prostates were lower [albeit not significantly (p>0.05)] in the test group, relative to the DC group. Serum prostatic acid phosphatase concentrations (U/L) decreased significantly (p<0.05) from 2.9 ± 0.2 in the DC group to 2.1 ± 0.7 in the test group. Histological findings corroborate these data. The testosterone: estradiol ratio (×10 3 ) was increased from 4.0 ± 0.2 in the DC group to 4.6 ± 0.2 in the test group. The test diet reduced the mass and secretory activity of the enlarged prostate and may act by increasing the testosterone: estradiol ratio.

show abstract

Section: Introductionmentioning

confidence: 99%

Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing <i>Telfairia occidentalis</i> seeds

Ejike

Ezeanyika²

2011

Afr. J. Trad. Compl. Alt. Med.

View full text Add to dashboard Cite

show abstract

“…In health economics, the number of DCE studies has sharply increased during the past decade [8][9][10][11][12]. More specifically, many DCE applications have aimed to evaluate the health and non-health dimensions of medical treatments, for example: miscarriage management [13]; varicella vaccination [14]; insulin mixtures [15]; alcoholism medication [16]; colorectal cancer screening [17]; weight loss programmes [18]; knee injuries detection [19]; and lower urinary tract symptoms [20]. In Table 1, we provide a nonexhaustive list of empirical papers using DCE to value medical interventions along with the dimensions that were assessed.…”

Section: Related Workmentioning

confidence: 99%

“…Roux et al [18] Weight loss programmes Programme cost, travel time to programme, amount of doctor involvement, programme components emphasised, focus of programme Bryan et al [19] Knee injury detection % chance of requiring arthroscopy, time from initial consultation to end of treatment, % chance that knee problem is completely resolved, total cost to the patient Watson et al [20] Lower urinary tract symptoms Time to symptom improvement, treatment decreases prostate size, sexual side effects of treatment, nonsexual side effects of treatment, treatment cost, % chance of surgery abstinence is negatively related to withdrawal symptoms. The medication precisely increases the success rate by decreasing these withdrawal symptoms.…”

Section: Framework For Analysismentioning

confidence: 99%

Assessing preferences for improved smoking cessation medications: a discrete choice experiment

Marti

2011

Eur J Health Econ

View full text Add to dashboard Cite

Background The use of smoking cessation medications can considerably enhance the long-term abstinence rate at a reasonable cost, but only a small proportion of quitters seek medical assistance. The objective of this study was to evaluate the factors that influence the decision to use such treatments and the willingness-to-pay of smokers for improved cessation drugs. Method A discrete choice experiment was conducted amongst smokers in the French-speaking part of Switzerland. Choice sets consisted of two hypothetical medications described via five attributes (price, efficacy, possibility of minor side effects, attenuation of weight gain and availability) and an opt-out option. Various discrete choice models were estimated to analyse both the factors that influence treatment choice and those that influence the overall propensity to use a smoking cessation medication. Results Our results indicate that smokers are willing to pay for higher efficacy, less-frequent side effects and prevention of weight gain. Whether the drug is available overthe-counter or on medical prescription is of secondary importance. In addition, we show that there are several individual-specific factors influencing the decision to use such medications, including education level. Results also indicate substantial preference heterogeneity. Conclusion This study shows that there is a potential demand for improved cessation medications. Broader usage could be reached through lower out-of-pocket price and greater efficacy. Secondary aspects such as side effects and weight gain should also be taken into consideration.

show abstract

“…The attributes of a 5ARI (dutasteride) and alfa blockers were investigated in a discrete choice study in community dwelling men (>40 years) in the UK (Watson et al 2004). Using willingness to pay as a measure of preference for the defined drug profiles, respondents were worse off (by almost £12 monthly) if they received alfa blockers compared with no medication.…”

Section: Medical Therapymentioning

confidence: 99%

“…showed that the respondents were willing to wait 13, 2, and 8 months longer for symptom improvement in exchange for reduced prostate size, and an absolute 1% decrease in the risks of AUR and surgery, respectively (Watson et al 2004). …”

Section: Table 1 | Evidence Base Included In the Reviewmentioning

confidence: 99%

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

Thomson¹

2005

View full text Add to dashboard Cite

show abstract

Eliciting Preferences for Drug Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Abstract: Given the attribute levels of BPH medical treatment, overall community dwelling men preferred the 5alpha-reductase inhibitor over alpha-blockers. In the interests of shared decision making it is important to consider the importance of eliciting the preferences of patients with BPH.

Cited by 63 publications

References 11 publications

Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing <i>Telfairia occidentalis</i> seeds

Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing <i>Telfairia occidentalis</i> seeds

Assessing preferences for improved smoking cessation medications: a discrete choice experiment

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

Contact Info

Product

Resources

About